SCHEMBL3687779

SCHEMBL3687779

N#CC1CCN(C(=O)c2nc3c(C(F)(F)F)cc(-c4ccoc4)cn3c2Cl)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.38
CCNT1 O60563 2/20 0.35
CCNK O75909 2/20 0.35
CCNE1 P24864 2/20 0.35
CDK2 P24941 2/20 0.35
CDK9 P50750 2/20 0.35
CDK12 Q9NYV4 2/20 0.35
TRPV1 Q8NER1 1/20 0.35
RBP4 P02753 3/20 0.34
HSD11B1 P28845 1/20 0.34
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33
KDM1A O60341 1/20 0.33
SCN9A Q15858 1/20 0.33
KDM5A P29375 1/20 0.33
MGLL Q99685 1/20 0.33
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
SCD5 Q86SK9 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3694905 0.89 HDAC4 (0.42) TRPV1RBP4HSD11B1TYRO3MERTK
SCHEMBL3645737 0.89 HDAC4 (0.42) TRPV1RBP4HSD11B1TYRO3MERTK
SCHEMBL3789320 0.88 KCNH2 (0.36) TRPV1RBP4HSD11B1TYRO3MERTK
SCHEMBL3650416 0.88 KCNH2 (0.36) TRPV1RBP4HSD11B1TYRO3MERTK
Hydrochloric Acid SCHEMBL3683913 0.87 KCNH2 (0.35) TRPV1RBP4HSD11B1TYRO3MERTK
SCHEMBL3793710 0.87 KDM1A (0.38) TRPV1RBP4HSD11B1TYRO3MERTK
SCHEMBL3693532 0.86 HSD11B1 (0.38) TRPV1HSD11B1TYRO3MERTKMGLL
SCHEMBL3692964 0.85 SCD5 (0.48) RBP4SCD5
SCHEMBL3790727 0.85 EPHX2 (0.38) TRPV1TYRO3MERTKKDM5AEPHX2
SCHEMBL3691242 0.85 SCD5 (0.48) RBP4SCD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 LRRK2 1380/4885CCNT1 1723/4885CCNK 2079/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 LRRK2 1380/4885CCNT1 1723/4885CCNK 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.